Company Overview

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular diseases, with an emphasis on improving anticoagulation care for patients with mechanical heart valves. The company’s core objective is to address limitations of existing anticoagulant therapies through drug candidates designed to offer more predictable dosing and improved safety profiles. Cadrenal operates within the biotechnology and pharmaceutical research industry and does not currently generate commercial revenue.

The company’s primary asset is tecarfarin, an oral vitamin K antagonist anticoagulant originally developed outside the company and later acquired for continued clinical development. Tecarfarin is intended to serve patient populations where existing anticoagulants, such as warfarin, present management challenges. Cadrenal Therapeutics became a publicly traded company in 2022 and is listed on Nasdaq under the ticker CVKD. Its evolution reflects a strategic focus on repurposing and advancing late-stage cardiovascular drug candidates rather than maintaining a broad discovery platform.

Business Operations

Cadrenal Therapeutics operates as a single-segment biotechnology company, with substantially all activities centered on the development of tecarfarin. The company’s operations include clinical trial planning, regulatory engagement, intellectual property management, and corporate administration. As a clinical-stage entity, it does not manufacture products at scale and relies on third-party contractors for clinical research, regulatory support, and other specialized services.

Operations are primarily U.S.-based, with clinical and regulatory activities aligned with the U.S. Food and Drug Administration (FDA) framework. The company does not report material international revenue or commercial operations, and its business model is dependent on capital raised through equity financings and strategic transactions rather than product sales. Data regarding additional operating segments or revenue-generating business units is inconclusive based on available public sources.

Strategic Position & Investments

Cadrenal’s strategic direction is centered on advancing tecarfarin through clinical development toward potential regulatory approval, particularly for patients with mechanical heart valves, a population with limited anticoagulation options. The company positions tecarfarin as a differentiated therapy due to its metabolism pathway, which may reduce drug-drug interactions compared to warfarin, though clinical validation remains ongoing.

The company has not disclosed a diversified portfolio of subsidiaries or material equity investments in other biotechnology firms. Strategic growth initiatives primarily involve securing additional financing, conducting clinical trials, and exploring potential licensing or partnership opportunities. Public disclosures do not indicate completed mergers or acquisitions beyond the acquisition of rights to tecarfarin; information on additional investments or emerging technology platforms is limited or not publicly detailed.

Geographic Footprint

Cadrenal Therapeutics is headquartered in the United States, with its principal executive offices located in California. The company’s operational footprint is largely domestic, reflecting its focus on U.S. regulatory pathways and U.S.-based clinical development activities.

While Cadrenal may engage international clinical research organizations or advisors, it does not report significant physical operations, offices, or revenue-generating activities outside the United States. Its global presence is therefore best characterized as indirect and development-focused rather than operationally international.

Leadership & Governance

Cadrenal Therapeutics is led by executives with experience in biotechnology, pharmaceuticals, and corporate finance. Leadership emphasizes capital discipline, regulatory execution, and targeted development of cardiovascular therapies rather than broad pipeline expansion. The company operates under a board-governed structure typical of U.S. public life sciences companies.

Key executives include:

• Quang X. Pham – Founder, President, and Chief Executive Officer
• Richard J. King – Chief Financial Officer
• Michael R. Anderson – Chief Medical Officer

Public disclosures do not consistently detail a formal leadership philosophy beyond advancing shareholder value through disciplined clinical development; further qualitative detail is inconclusive based on available public sources.